AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03391297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
Study NCT03391297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
Study NCT02308111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study.
Study NCT02308111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
Study NCT00012376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study NCT00012376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study NCT04183790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration
Study NCT04183790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Mono tablet for oral administration.
Study NCT03349606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
Study NCT03349606 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]FLB 457
Description: PET radiotracer
Study NCT03419195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise training
Description: Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
Study NCT01890707 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: General Anesthesia
Description: Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
Study NCT01890707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Sedation
Description: IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
Study NCT02381509 — intervention group
Intervention type: DEVICE
Intervention: IVC Filter
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300mg
Description: Single dose of Tafenoquine give on Day 3 only
Study NCT00012376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00012376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 600mg
Description: Single dose of Tafenoquine given on Day 3 only
Study NCT04505930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventional HPV vaccination video modules
Description: The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 1200mg
Description: 400mg Dose of Tafenoquine given on each of the three consecutive dosing days
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: moxifloxacine given on Day 3 only
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Study NCT04505930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Vaccination Education
Description: Education session conducted using only handouts of vaccinations including HPV
Study NCT01928914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Study NCT02682290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Expectoration and measurement of sputum rheological properties
Study NCT01066481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01913539 5 mg
Description: PF-01913539 5 mg three times daily for 6 months
Study NCT02690818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularly scheduled LTBI medication reminder text messages
Description: Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.
Study NCT01066481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily for 6 months
Study NCT01987804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 100 i.u.
Study NCT01987804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 400 i.u.
Study NCT01987804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02542306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrinogen concentrate
Description: Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
Study NCT00681863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.125 mg BID
Description: titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
Study NCT00681863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.0625 mg QD
Description: dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
Study NCT00681863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.125 mg TID
Description: titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
Study NCT00681863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.25 mg BID
Description: titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
Study NCT00681863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.0625 mg BID
Description: 0.0625 mg BID given for first 4 wks of treatment
Study NCT03150121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
Study NCT03150121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine lavage
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
Study NCT03150121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 5-10mL of blood will be drawn from participants.
Study NCT03150121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: 5-10mL of blood will be drawn from participants.
Study NCT03150121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine lavage catheter
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
Study NCT03150121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine lavage catheter
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
Study NCT03131999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate 400Mg Capsule
Description: Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
Study NCT03131999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
Study NCT05044442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity continous training
Description: Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
Study NCT05044442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
Study NCT01323998 — intervention group
Intervention type: DRUG
Intervention: 5ARI
Description: Dutasteride or Finasteride
Study NCT00874627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: sublingual administration of milk
Study NCT01323998 — intervention group
Intervention type: DRUG
Intervention: AB
Description: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Study NCT01844934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
Study NCT03239275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biocreative therapy
Study NCT03239275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biocreative therapy
Study NCT00599183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI-Diffusion Tensor Imaging and Tractrography
Description: MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
Study NCT04110977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile application (reminder app)
Description: This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
Study NCT04110977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application (reminder app)
Description: This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
Study NCT03796455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule + Powder supplementation
Description: For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
Study NCT03796455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsule + Powder supplementation
Description: For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
Study NCT03796455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable tracer infusion
Description: labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
Study NCT03796455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stable tracer infusion
Description: labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
Study NCT00874627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk
Description: placebo
Study NCT01551550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GDD
Description: The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
Study NCT01551550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GDD
Description: The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
Study NCT01551550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Graft
Description: For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
Study NCT01551550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericardial Graft
Description: For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
Study NCT02947932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: pre-ERCP intervention
Study NCT04240418 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
Study NCT04174170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Up to 3 mg pill
Study NCT04174170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Up to 150 mg pill
Study NCT04174170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill
Study NCT02947932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: post-ERCP intervention in high risk patients
Study NCT00987467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin 0.05% ophthalmic
Description: Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
Study NCT04174170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill
Study NCT00410566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.03mg/kg body weight IV
Study NCT00410566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.1mg/kg body weight IV
Study NCT00410566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.3mg/kg body weight IV
Study NCT00410566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 0.6mg/kg body weight IV
Study NCT00410566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhASM
Description: Single dose of 1.0mg/kg body weight IV
Study NCT01361399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Description: Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
Study NCT01361399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Single oral application of Aspirin (as lozenge)
Study NCT01361399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: Single oral application of Lidocain (as lozenge)
Study NCT01361399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral application of Placebo (as lozenge)
Study NCT00988234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGPP
Description: ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
Study NCT00988234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGTPP
Description: ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
Study NCT00988234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGLP
Description: ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
Study NCT00988234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGTLP
Description: ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
Study NCT04193059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.